Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes

2020 ◽  
Author(s):  
Olatunji B. Alese ◽  
Katerina Zakka ◽  
Xingyue Huo ◽  
Renjian Jiang ◽  
Walid L. Shaib ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Survival Outcomes ◽  
Perioperative Therapy ◽  
Cancer Pattern

scholarly journals Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors

HPB ◽  
2016 ◽  
Vol 18 (9) ◽  
pp. 756-763 ◽  
Author(s):  
Iswanto Sucandy ◽  
Susannah Cheek ◽  
Benjamin J. Golas ◽  
Allan Tsung ◽  
David A. Geller ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Metastatic Colorectal Cancer ◽  
Liver Tumors ◽  
Survival Outcomes ◽  
Longterm Survival

scholarly journals Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

2020 ◽  
Vol 31 (1) ◽  
pp. 88-95 ◽  
Author(s):  
T. Yoshino ◽  
J.M. Cleary ◽  
E. Van Cutsem ◽  
R.J. Mayer ◽  
A. Ohtsu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Survival Outcomes ◽  
Colorectal Cancer Patients

Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab

2019 ◽  
Vol 14 (6) ◽  
pp. 743-748
Author(s):  
Huezin H. Lim ◽  
Ashley M. Hopkins ◽  
Andrew Rowland ◽  
Hoi Y. Yuen ◽  
Christos S. Karapetis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adverse Events ◽  
Metastatic Colorectal Cancer ◽  
Survival Outcomes

scholarly journals 511P Real-world survival outcomes of Asian metastatic colorectal cancer patients undergoing hepatectomy from the AsianmCRCRegistry

2020 ◽  
Vol 31 ◽  
pp. S456
Author(s):  
C. Teh ◽  
S. Cai ◽  
J-K. Lin ◽  
Y.S. Park ◽  
T.W. Kim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Real World ◽  
Survival Outcomes ◽  
Colorectal Cancer Patients

Perioperative therapy in patients with metastatic colorectal cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18231-e18231
Author(s):  
Olatunji B. Alese ◽  
Katerina Mary Zakka ◽  
Xingyue Huo ◽  
Renjian Jiang ◽  
Walid Labib Shaib ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Multivariate Analyses ◽  
Stage Iv ◽  
Tumor Location ◽  
Primary Site ◽  
Perioperative Therapy ◽  
Younger Age ◽  
Male Preponderance ◽  
Metastatic Sites

e18231 Background: Knowledge about perioperative systemic therapy in metastatic colorectal cancer (mCRC) is limited. We aim to describe the nationwide pattern of use and survival outcomes of patients with mCRC treated with surgical resection. Methods: Data were obtained from all US hospitals that contributed to the National Cancer Database (NCDB) between 2004 and 2013. Univariate and multivariate analyses was done to identify factors associated with patient outcome. Results: A total of 61,940 patients with stage IV CRC older than 18 years were identified. Mean age was 63.4 years (SD±14), with a male preponderance (54.8%). About 80% were Caucasian and 69.9% had colon cancer. Compared to medical treatment only, resection of both primary and metastatic sites (13.5%; HR 0.40; 0.37-0.44; p < 0.001), or primary site resection alone (49.2%; HR 0.52; 0.48-0.56; p < 0.001) were associated with improved overall survival (OS). Other co-variates associated with improved survival included younger age group, year of diagnosis (2009-2013), colon tumor location, and < 3 metastatic sites (Table). Five-year OS for resection of primary and metastatic site (28.2%) was higher than for primary site resection alone (14.9%) or no surgical treatment (4.7%). Conclusions: Resection of metastatic sites or primary tumor was associated with improved survival in patients with stage IV CRC.[Table: see text]

Skeletal muscle loss under chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 4025-4025 ◽  
Author(s):  
Claire Gallois ◽  
Camille Bourillon ◽  
Edouard Auclin ◽  
Pascal Artru ◽  
Astrid Lievre ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Skeletal Muscle ◽  
Multivariate Analysis ◽  
Metastatic Colorectal Cancer ◽  
Survival Outcomes ◽  
Muscle Loss ◽  
Skeletal Muscle Index ◽  
Nutritional Factors ◽  
Multicenter Observational Study ◽  
Skeletal Muscle Loss

4025 Background: We showed in a previous work that “Patient Generated-Subjective Global Assessment” (PG-SGA) was independently associated with survival and treatment toxicities in non-pretreated metastatic colorectal cancer (mCRC) patients. We have evaluated here if muscle mass in these patients can provide useful additional information for clinical practice. The objective of the present work was to evaluate the association between baseline sarcopenia, and the variation of the Skeletal Muscle Index (SMI) under treatment with survival and chemotherapy-related toxicities in our population of non-pretreated mCRC patients. Methods: This prospective multicenter observational study enrolled non-pretreated mCRC patients. Measurement of SMI was performed on routine CT scan at day 0 (D0) and day 60 (D60). PG-SGA score and other nutritional factors were collected at D0. Progression-free survival (PFS) and overall survival (OS) were calculated from treatment start. Treatment related toxicities were registered according to the NCI CTCAE v4.0. Results: 149 patients were included in eight French centers from 7/2013 to 11/2016. Sarcopenia at baseline was not significantly associated with survival outcomes or chemotherapy-related toxicities. The best cut-point value of SMI variation (between D0 and D60) for OS prediction obtained with a log-rank maximisation method was -14%. The decrease in SMI > 14%, with a median follow-up of 23 months, was significantly associated with shorter PFS (6 vs 9 mo; HR 1.8, 95%CI 1.1-3.1, p = 0.02) and OS (8.5 vs 26 mo; HR 2.4, 95%CI 1.3-4.4, p = 0.004), independently of hypoalbuminemia and malnutrition defined by PG-SGA, in multivariate analysis. 40% of patients with a SMI decrease > 14%, and 22% of patients with a SMI increase or stable or decrease < 14% developed grade ≥ 2 clinical toxicities (OR 3.0, 95%CI 1.2-7.7, p = 0.02), but the difference was not statistically significant in multivariate analysis (OR 2.3. 95%CI 0.8-6.7, p = 0.1). Conclusions: To our knowledge, this study is the first study assessing the association of skeletal muscle loss with survival and treatment toxicities in patients with mCRC prospectively. In our population of non pre-treated mCRC patients, baseline sarcopenia was not associated with poor survival outcomes, but the decrease in SMI > 14% during the first two months of treatment was significantly associated with decreased PFS and OS, independently of other prognostic and nutritional factors.

Sign in / Sign up

Export Citation Format

Share Document